Phospho-CCNH (Thr315) Antibody

What is Cyclin H and why is the phosphorylation at Thr315 significant?

Cyclin H (CCNH) is a 37.6 kDa protein that functions as a component of the CDK-activating kinase (CAK) complex, which plays a critical role in cell cycle regulation. The phosphorylation at threonine 315 is a post-translational modification that regulates Cyclin H activity and interactions with other proteins in the cell cycle machinery. This specific phosphorylation event is implicated in modulating CAK activity, which in turn affects downstream cell cycle progression and transcriptional regulation. Understanding this modification provides insights into fundamental cellular processes and potential dysregulation in disease states .

What detection methods can be used with Phospho-CCNH (Thr315) Antibody?

Phospho-CCNH (Thr315) Antibody can be utilized in multiple experimental techniques including:

• Western Blotting (WB): For detecting denatured phosphorylated Cyclin H in protein lysates

• Immunohistochemistry (IHC): For visualizing phospho-Cyclin H in tissue sections

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization studies

• Cell-Based ELISA: For high-throughput quantitative analysis in cultured cells

The antibody shows confirmed reactivity with human and mouse samples, with predicted reactivity in additional species including pig, zebrafish, horse, sheep, rabbit, dog, and chicken . For optimal results, each application requires specific optimization of antibody dilution and sample preparation protocols.

How should samples be prepared to preserve phosphorylation status?

Sample preparation is crucial for phospho-specific antibody detection. To preserve the phosphorylation status of Cyclin H at Thr315:

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all lysis and extraction buffers

• Maintain samples at 4°C during processing to minimize dephosphorylation

• Use appropriate lysis buffers containing detergents (e.g., NP-40 or Triton X-100) to solubilize membrane-associated proteins while preserving phosphorylation

• Process samples rapidly to minimize degradation and dephosphorylation events

• Consider flash-freezing tissues immediately after collection in liquid nitrogen

These precautions are essential as phosphorylation is a labile modification that can be rapidly lost during sample handling .

How can I validate the specificity of Phospho-CCNH (Thr315) Antibody signals?

Validating the specificity of phospho-specific antibody signals requires multiple controls:

• Dephosphorylation control: Treat a portion of your sample with lambda phosphatase to remove phosphate groups and confirm signal loss

• Blocking peptide competition: Pre-incubate the antibody with the phosphorylated immunogen peptide to block specific binding

• Non-phosphorylated control: Compare signals between phosphorylated and non-phosphorylated forms using total Cyclin H antibody

• Knockout/knockdown validation: Use CCNH knockout or knockdown samples as negative controls

• Phosphorylation induction: Use treatments known to induce Thr315 phosphorylation as positive controls

A combination of these approaches provides robust validation of antibody specificity, particularly important when working with novel experimental systems or when unexpected results are observed .

What are the optimal protocols for detecting low-abundance Phospho-CCNH (Thr315) in various sample types?

For detecting low-abundance phosphorylated Cyclin H:

For Western Blotting:

• Enrich phosphoproteins using phosphoprotein enrichment kits prior to SDS-PAGE

• Use high-sensitivity detection systems (ECL Prime or Femto)

• Increase protein loading (50-100 μg total protein)

• Optimize transfer conditions for proteins in the 38 kDa range

• Consider using PVDF membranes which may provide better retention of phosphoproteins

• Use 5% BSA instead of milk for blocking and antibody diluent

For Immunoprecipitation followed by Western Blotting:

• Immunoprecipitate with total Cyclin H antibody first, then probe with phospho-specific antibody

• Use at least 500 μg of total protein lysate for immunoprecipitation

• Include phosphatase inhibitors throughout the procedure

For Cell-Based ELISA:

• Use a minimum of 5000 cells per well for reliable detection

• Compare phospho-signal to total protein signal for normalization

• Include GAPDH as an internal loading control

How can I multiplex Phospho-CCNH (Thr315) detection with other phospho-proteins?

Multiplexing phospho-protein detection requires careful experimental design:

• Sequential immunoblotting: Strip and reprobe membranes, ensuring complete stripping verification between each antibody

• Fluorescent multiplexing: Use antibodies from different host species coupled with spectrally distinct fluorescent secondary antibodies

• Mass spectrometry approaches: For comprehensive phosphorylation profiling, consider SureQuant pTyr enrichment methodology that allows for targeted monitoring of multiple phosphorylation events simultaneously

• Cell-Based ELISA with multiple controls: Parallel wells with total protein and different phospho-protein antibodies

When multiplexing, carefully consider antibody cross-reactivity and optimize blocking conditions to minimize background. For mass spectrometry approaches, incorporate heavy-labeled internal standard peptides for accurate quantification and use phosphotyrosine-specific enrichment with combined antibodies (4G10, PT66, pY100) for comprehensive coverage .

How should I interpret changes in Phospho-CCNH (Thr315) levels relative to total CCNH?

Interpreting phosphorylation data requires consideration of both phospho-specific and total protein signals:

• Calculate the phospho-to-total protein ratio to normalize for changes in total protein expression

• Consider temporal dynamics—phosphorylation changes often precede observable phenotypic outcomes

• Correlate with relevant functional assays (e.g., cell cycle analysis, CDK activity assays)

• Compare with other components of the CAK complex (CDK7, MAT1) for comprehensive pathway analysis

What are common causes of false positives or negatives when working with Phospho-CCNH (Thr315) Antibody?

Common causes of false positives:

• Cross-reactivity with similar phosphorylation motifs in other proteins

• Insufficient blocking leading to non-specific binding

• Overly sensitive detection systems amplifying background

• Sample contamination with phosphatase inhibitors affecting control samples

Common causes of false negatives:

• Phosphorylation loss during sample preparation

• Insufficient antigen retrieval for fixed tissues

• Epitope masking due to protein-protein interactions

• Suboptimal antibody concentration or incubation conditions

• Rapid dephosphorylation kinetics in your experimental system

To mitigate these issues, always include proper positive and negative controls, optimize sample preparation protocols, and validate results using complementary techniques .

How can I resolve inconsistent results between different detection methods?

When facing inconsistent results between methods:

• Consider method sensitivities: Cell-based ELISA typically offers higher sensitivity than Western blotting

• Evaluate sample preparation differences: Each method may require different sample processing that affects phosphorylation preservation

• Assess antibody performance in different contexts: The antibody may perform differently under native (ELISA/IF) versus denatured (WB) conditions

• Check for interfering factors: Buffer components or contaminating proteins may affect specific methods differently

• Confirm with orthogonal approaches: Use mass spectrometry-based phosphoproteomics as an antibody-independent method to validate key findings

Systematic troubleshooting should include side-by-side comparison using standardized samples and detailed documentation of all experimental variables .

How can Phospho-CCNH (Thr315) be used to study cell cycle dysregulation in cancer models?

Phospho-CCNH (Thr315) antibodies provide valuable tools for investigating cell cycle dysregulation in cancer:

• Comparative analysis: Profile phospho-CCNH levels across normal tissues, tumor cell lines, and patient samples to identify aberrant phosphorylation

• Drug response studies: Monitor phospho-CCNH changes following treatment with CDK inhibitors, chemotherapeutics, or targeted therapies

• Pathway mapping: Combine with other CAK component analyses to characterize altered signaling networks

• Prognostic indicator research: Correlate phospho-CCNH levels with clinical outcomes in patient cohorts

• Mechanistic studies: Use phospho-mutants (T315A or T315E) to investigate functional consequences of this modification

For colorectal cancer studies, phosphotyrosine profiling has provided complementary insights to traditional genomic and transcriptomic characterization, identifying patient-specific oncogenic mechanisms. Similar approaches could be applied using phospho-CCNH as a biomarker .

What experimental designs are optimal for studying dynamic changes in CCNH phosphorylation?

To effectively capture dynamic phosphorylation changes:

• Time-course experiments: Collect samples at multiple timepoints after stimulus application

• Synchronization protocols: Use cell cycle synchronization methods (serum starvation, double thymidine block, nocodazole arrest) followed by release to track cell cycle-dependent phosphorylation

• Single-cell analysis: Consider phospho-flow cytometry or imaging approaches to address cell-to-cell variability

• Pulse-chase designs: Use kinase inhibitors or activators in pulse-chase experiments to determine phosphorylation and dephosphorylation kinetics

• Quantitative analysis: Employ cell-based ELISA kits for high-throughput quantitative assessment across multiple conditions

When designing these experiments, include appropriate normalization controls (GAPDH, total protein) and consider the half-life of the phosphorylation event, which may require closely spaced timepoints for rapidly changing modifications .

How can I integrate Phospho-CCNH (Thr315) analysis with other omics approaches?

Multi-omics integration enhances the value of phosphorylation data:

• Phosphoproteomics integration: Combine targeted phospho-CCNH analysis with global phosphoproteomic profiling to place the modification in broader signaling context

• Transcriptomics correlation: Link phospho-CCNH levels to transcriptional changes of cell cycle genes to establish functional consequences

• Genomic context: Analyze phospho-CCNH in the context of cancer mutations affecting the CDK-activating kinase pathway

• Protein interaction networks: Use proximity labeling or co-immunoprecipitation to identify phosphorylation-dependent interaction partners

• Functional screening: Combine with CRISPR or RNAi screens to identify synthetic interactions with CCNH phosphorylation status

SureQuant targeted phosphoproteomic approaches have demonstrated value in colorectal tumor analysis, requiring minimal sample input while providing mechanistic insights complementary to traditional biomarkers. Similar strategies could be applied to investigate CCNH phosphorylation in various disease contexts .

How does antibody-based detection of Phospho-CCNH (Thr315) compare with mass spectrometry approaches?

For comprehensive phosphorylation profiling, targeted mass spectrometry approaches like SureQuant can complement antibody-based detection, particularly when analyzing complex clinical samples. The combined approach provides both targeted quantification and broader pathway insights .

What are the considerations for studying Phospho-CCNH (Thr315) in different model systems?

Different experimental models present unique considerations:

Cell lines:

• Ensure cell line authenticity and passage number consistency

• Consider baseline phosphorylation levels which vary between cell types

• Growth conditions (confluence, serum, oxygen) affect phosphorylation status

Animal models:

• Confirm antibody cross-reactivity with the species being studied

• Consider tissue-specific expression patterns of CCNH

• Optimize tissue collection and preservation to maintain phosphorylation

Patient samples:

• Standardize collection procedures to minimize ischemic time

• Document clinical variables that may affect phosphorylation

• Consider tumor heterogeneity when interpreting results

• Use parallel FFPE and frozen samples for validation

3D cultures and organoids:

• May require modified lysis protocols to ensure complete protein extraction

• Consider regional differences in phosphorylation within 3D structures

• Validate antibody performance in these complex systems

The antibody shows confirmed reactivity with human and mouse samples, with predicted reactivity in additional species that should be experimentally validated before extensive studies .

How can I establish correlations between Phospho-CCNH (Thr315) levels and functional outcomes?

To establish meaningful correlations between phosphorylation and function:

• Functional readouts: Pair phosphorylation analysis with relevant functional assays:

  • Cell cycle progression (flow cytometry)

  • CDK7 kinase activity assays

  • Transcriptional activity of CDK7 targets

  • Cell proliferation rates

  • Response to cellular stressors

• Genetic manipulation:

  • Generate phospho-mimetic (T315E) or phospho-deficient (T315A) mutants

  • Use CRISPR/Cas9 to introduce these mutations at endogenous loci

  • Compare phenotypes with wild-type under various conditions

• Pharmacological approaches:

  • Use specific kinase inhibitors to modulate the pathway

  • Correlate drug dose with phosphorylation level and functional outcome

  • Establish dose-response curves for both phosphorylation and function

• Mathematical modeling:

  • Develop quantitative models incorporating phosphorylation kinetics

  • Use systems biology approaches to predict functional outcomes

  • Validate model predictions experimentally

• Clinical correlations:

  • For patient samples, correlate phospho-CCNH levels with clinical parameters

  • Consider multivariate analysis to account for confounding factors

  • Validate findings across independent patient cohorts

These approaches provide robust evidence for causal relationships between phosphorylation events and biological functions, essential for mechanistic understanding and potential therapeutic targeting .